74 Quick summary: Medical researchers have engineered advanced CAR T cells that specifically destroy bladder cancer cells by targeting a precise surface protein called MUC16, which is largely absent from healthy tissue. Animal testing demonstrated that administering these immune cells directly through a catheter controlled tumour growth and extended survival without letting the treatment leak into the rest of the body, successfully overcoming the toxicity risks that usually plague solid tumour therapies. For clinical healthcare practice and patient well-being, this readily implementable delivery method marks a massive step towards establishing effective bladder sparing treatments, potentially saving hundreds of thousands of global patients from the profound psychological trauma and severe physical complications associated with total organ removal. Researchers at Weill Cornell Medicine, Cedars-Sinai Medical Center, and Roswell Park Comprehensive Cancer Center have developed genetically engineered CAR T cells that specifically target and kill bladder cancer cells. The study, published on 26th June in the Journal of Experimental Medicine, demonstrates that direct delivery of these CAR T cells via a catheter can control bladder tumors in mice, raising hopes that a similar approach may be effective in humans. Approximately 600,000 new cases of bladder cancer are diagnosed worldwide each year, including about 80,000 in the US alone. Treatment generally involves surgical removal of the tumor followed by chemotherapy or immunotherapy, but these approaches carry high recurrence and progression rates, often necessitating complete removal of the bladder, a life-altering procedure that can lead to significant complications. “For patients facing high-risk bladder cancer, options have historically been limited, highly morbid, and life-altering. This reality has driven a critical, renewed interest in developing effective bladder-sparing approaches,” said Parwiz Abrahimi, first author of the study and a urologic oncologist at Cedars-Sinai Medical Center. The study was co-led by Professors Taha Merghoub and Jedd Wolchok of Weill Cornell Medicine, alongside Professor Renier J. Brentjens of Roswell Park. CAR T cells are immune cells genetically engineered to express an artificial receptor protein capable of specifically targeting cancer cells. They have been successfully used to treat many types of blood cancer, but their success against solid tumors has so far been limited due to poor tumor infiltration and off-target toxicity. To address these challenges, the researchers created CAR T cells targeting a protein called MUC16, which is highly expressed on the surface of many bladder cancer cells, including types resistant to existing therapies, but largely absent from normal bladder cells and other healthy tissues. These CAR T cells were able to kill MUC16-positive tumors grown in the lab from patient-derived bladder cancer cells. The team then tested the CAR T cells in mice implanted with human bladder cancer cells. When administered intravenously, the cells were ineffective. When delivered directly into the bladder via catheter, known as intravesical delivery, they reduced tumor growth and extended survival. Critically, the CAR T cells were unable to spread into the rest of the body when administered this way, minimising the risk of side effects in other tissues. “Development of engineered T cells for solid tumors has been challenging, in part due to normal tissue expression of potential target antigens. Using a compartmentalised delivery system allows us to overcome this hurdle and hopefully come one step closer to broader use of CAR and transgenic T cells for common solid tumors, like bladder cancer,” said Wolchok. “Our findings establish MUC16 as a clinically relevant target for CAR T cell therapy in bladder cancer, and highlight that intravesical delivery, a commonly used administration route in urological practice, represents a feasible, effective, and readily implementable strategy for adoptive CAR T cell transfer. This approach could be useful for both initial treatment of bladder cancer as well as treatment-refractory subsets of tumors, offering an attractive therapeutic option for patients who may have limited therapeutic alternatives besides bladder removal,” said Merghoub. Further studies are needed to translate these findings to human patients, but researchers say the results mark a significant step toward less invasive options for managing a disease that remains highly prevalent globally.